Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

By R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. D. Arvis, M. Ahn and 9 more. The Lancet, 2016

5,819 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/90a6f784565f3fbafbbf2dd7c28186feeebfa789

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. M. Postow
3. C. Robert
4. F. Hodi
5. M. Hellmann
6. K. Kerr
7. Razelle Kurzrock
8. M. Callahan

In Pulmonary and Respiratory Medicine

1. Gregory Riely
2. L. Sequist
3. J. Engelman
4. J. Gong
5. S. Reddi
6. Alexander Chehrazi-Raffle
7. Ravi Salgia
8. Marc Ladanyi

In Radiology, Nuclear Medicine and Imaging

1. J. Engelman
2. Jeffrey L. Wrana
3. C. Roy

Citations in the corpus

• Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “Pembrolizumab was approved by the FDA on 2 October 2015 for metastatic NSCLC patients who progressed after platinum-based therapy or EGFR- or ALK-targeted therapy and are positive for PDL-1, via accelerated approval based on the randomized, open-labeled, phase II/III study, Keynote-010 trial, showin”
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, neutral): “KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
• EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis (2016, result): “Such findings are consistent with recent prospective data from the CheckMate 057 and KEYNOTE 010 trials (9, 10).”
• The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (2021, methodology): “Trial data have revealed that PD-L1 evaluated on archival or fresh biopsy samples yielded comparable clinical outcomes.(46) Aside from preanalytical issues, the most important criteria for sample adequacy are the presence of at least 100 assessable tumor cells for PD-L1 assessment.”